| HOME >> MEDICINE >> TECHNOLOGY |
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Lymphoma Drugs 394
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Lymphoma Drugs 394
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Lymphoma Drugs 396
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs 398
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Lymphoma Drugs 400
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs 403
Table 26: New and Unique Target Strategies in Preclinical Development of Lymphoma Drugs 405
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Lymphoma Drugs 406
Table 28: Target Strategies of Suspended and Terminated Lymphoma Drugs 408
Table 29: Connecting Target Strategy with Its Profile Identification Number 410
Table 30: The Competition Through Close Mechanistic Approximation Among Lymphoma Drugs 591
Table 31: Overview of Compound Strategy Competition Among Lymphoma Drugs 598
Table 32: Overview of the Competitive Landscape of Small Molecule Based Lymphoma Drugs 600
Table 33: Competitive Comparison of Target Strategies of Small Molecule Lymphoma Drugs 601
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Lymphoma Drugs 604
Table 35: Overview of the Competitive Landscape of Peptide Based Lymphoma Drugs 611
Table 36: Pursued Target Strategies of Peptide Based Lymphoma Drugs 612
Table 37: Overview of the Competitive Landscape of Protein Based Lymphoma Drugs 613
Table 38: Competitive Comparison of Target Strategies of Protein Based Lymphoma Drugs 614
Table 39: Pursued Target Strategies of Protein Based Lymphoma Drugs 614
Ta
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |